Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-908662 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| BMS-908662 or Ipilimumab (A) | EXPERIMENTAL | - |
| BMS-908662 or Ipilimumab (B) | EXPERIMENTAL | - |
| BMS-908662 (A1) | EXPERIMENTAL | Phase 1 |
| Cetuximab (A1) | EXPERIMENTAL | Phase 1 |
| BMS-908662 (B1) | EXPERIMENTAL | Phase 2 |
| BMS-908662 + Cetuximab (B2) | EXPERIMENTAL | Phase 2 |
| Name | Type | Description |
|---|---|---|
| BMS-908662 | DRUG | Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously |
| Ipilimumab | DRUG | Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously |
| Cetuximab | DRUG | Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously |
Inclusion: * Male and female subjects ≥ 18 years of age with a histologic or cytologic diagnosis of Stage III or Stage IV (unresectable) melanoma * Enrollment to cohort expansion will be limited to only those subjects whose tumors demonstrate the B-Raf V600E mutation * ECOG ≤ 1 * Adequate organ \& ...
Top 20 of 80 competitors
BMS-908662 is an investigational small molecule being studied for the treatment of colorectal cancer and melanoma. It has been evaluated in Phase 1 clinical trials for these oncology indications.
BMS-908662 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY.
BMS-908662 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials for this asset have been completed.
BMS-908662 has been studied in two completed Phase 1 trials. NCT01086267 evaluated the drug alone or with cetuximab in advanced or metastatic colorectal cancer with K-RAS or B-RAF mutations. NCT01245556 evaluated the drug in combination with ipilimumab in advanced melanoma.
BMS-908662 is the primary identifier for this investigational compound. No alternative names have been established for this drug in clinical development.